Publications
Publications
- September 2021
- HBS Case Collection
Hester Pharmaceuticals (B): Securing Supply
By: Dante Roscini and John Masko
Abstract
In 2020, amid the COVID-19 pandemic and a rise in “reshoring” sentiment in the U.S., Hester Pharmaceuticals had to decide whether to build a new plant for its new oncology drug Akrozumab in Germany or in the U.S., or whether it should hire a contract manufacturing organization (CMO) to produce the drug. As it made its decision, Hester had to con
Keywords
COVID-19 Pandemic; Cost vs Benefits; Trade; Supply Chain; Global Strategy; Buildings and Facilities; Operations; Pharmaceutical Industry; Italy
Citation
Roscini, Dante, and John Masko. "Hester Pharmaceuticals (B): Securing Supply." Harvard Business School Supplement 722-009, September 2021.